Research/art/teacher profile of a person
Name and surname:
prof. MUDr. Martin Wawruch, PhD.
Document type:
Research/art/teacher profile of a person
The name of the university:
Comenius University Bratislava
The seat of the university:
Šafárikovo námestie 6, 818 06 Bratislava

I. - Basic information

I.1 - Surname
Wawruch
I.2 - Name
Martin
I.3 - Degrees
Prof. MUDr. PhD.
I.4 - Year of birth
1975
I.5 - Name of the workplace
Comenius University in Bratislava, Faculty of Medicine, Institute of Pharmacology and Clinical Pharmacology
I.6 - Address of the workplace
Sasinkova 4, 811 08 Bratislava
I.7 - Position
university teacher - Professor, Head of the Institute
I.8 - E-mail address
martin.wawruch@fmed.uniba.sk
I.9 - Hyperlink to the entry of a person in the Register of university staff
https://www.portalvs.sk/regzam/?surname=Wawruch&name=Martin&university=701000000&faculty=701010000&employment_state=yes&sort=surname&filter=Vyh%C4%BEada%C5%A5&do=filterForm-submit
I.10 - Name of the study field in which a person works at the university
Clinical Pharmacology
I.11 - ORCID iD
0000-0001-7672-1574

II. - Higher education and further qualification growth

II.1 - First degree of higher education
II.2 - Second degree of higher education
II.a - Name of the university or institution
Comenius University in Bratislava, Faculty of Medicine
II.b - Year
1999
II.c - Study field and programme
General Medicine
II.3 - Third degree of higher education
II.a - Name of the university or institution
Comenius University in Bratislava, Faculty of Medicine
II.b - Year
2003
II.c - Study field and programme
Clinical Pharmacology
II.4 - Associate professor
II.a - Name of the university or institution
Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin
II.b - Year
2007
II.c - Study field and programme
Pharmacology
II.5 - Professor
II.a - Name of the university or institution
Comenius University in Bratislava, Faculty of Medicine
II.b - Year
2014
II.c - Study field and programme
Clinical Pharmacology
II.6 - Doctor of Science (DrSc.)

III. - Current and previous employment

III.a - Occupation-position III.b - Institution III.c - Duration
Assistant Professor, Associate Professor, Full Professor Comenius University in Bratislava, Faculty of Medicine 1.11.2000 – until now
PhD student Faculty of Health and Social Care, Trnava University in Trnava 1.10. 1999 - 31. 10. 2000

IV. - Development of pedagogical, professional, language, digital and other skills

IV.a - Activity description, course name, other IV.b - Name of the institution IV.c - Year
Course in Drug Utilization Research The European Branch of the Special Ineterest Group for Drug Utilization Research, Szeged 2020
Sample size estimation ACREA, Praha 2019
Course in pharmacoepidemiolpgy International Society for Pharmacoepidemiology, Philadelphia 2019
Winter Course in Statistical Methods Used in Data Analysis SPSS CR, Bratislava 2009

V. - Overview of activities within the teaching career at the university

V.1 - Overview of the profile courses taught in the current academic year according to study programmes
V.1.a - Name of the profile course V.1.b - Study programme V.1.c - Degree V.1.d - Field of study
Pharmacology General Medicine I.+II. General Medicine
Pharmacology Dentistry I.+II. Dentistry, Dental Medicine
Clinical Pharmacology General Medicine I.+II. General Medicine
New drugs and strategies in pharmacotherapy General Medicine III. General Medicine
V.2 - Overview of the responsibility for the delivery, development and quality assurance of the study programme or its part at the university in the current academic year
V.2.a - Name of the study programme V.2.b - Degree V.2.c - Field of study
Pharmacology I.+II. General Medicine
Pharmacology I.+II. Dentistry, Dental Medicine
Clinical Pharmacology I.+II. General Medicine
Clinical Pharmacology III. General Medicine
V.3 - Overview of the responsibility for the development and quality of the field of habilitation procedure and inaugural procedure in the current academic year
V.3.a - Name of the field of habilitation procedure and inaugural procedure V.3.b - Study field to which it is assigned
Clinical Pharmacology General Medicine
V.4 - Overview of supervised final theses
V.4.1 - Number of currently supervised theses
V.4.b - Diploma (second degree)
3
V.4.c - Dissertation (third degree)
4
V.4.2 - Number of defended theses
V.4.b - Diploma (second degree)
20
V.4.c - Dissertation (third degree)
4
V.5 - Overview of other courses taught in the current academic year according to study programmes
V.5.a - Name of the course V.5.b - Study programme V.5.c - Degree V.5.d - Field of study
Clinical Pharmacology General Medicine I.+II. General Medicine
New drugs and strategies in pharmacotherapy all PhD. study programmes III. General Medicine

VI. - Overview of the research/artistic/other outputs

VI.1 - Overview of the research/artistic/other outputs and the corresponding citations
VI.1.1 - Number of the research/artistic/other outputs
VI.1.a - Overall
308
VI.1.b - Over the last six years
111
VI.1.2 - Number of the research/artistic/other outputs registered in the Web of Science or Scopus databases
VI.1.a - Overall
75
VI.1.b - Over the last six years
32
VI.1.3 - Number of citations corresponding to the research/artistic/other outputs
VI.1.a - Overall
543
VI.1.b - Over the last six years
288
VI.1.4 - Number of citations registered in the Web of Science or Scopus databases
VI.1.a - Overall
397
VI.1.b - Over the last six years
201
VI.1.5 - Number of invited lectures at the international, national level
VI.1.a - Overall
6
VI.1.b - Over the last six years
4
VI.2 - The most significant research/artistic/other outputs
1

Wawruch M, Wimmer G Jr, Murin J, Paduchova M, Tesar T, Hlinkova L, Slavkovsky P, Fabryova L, Aarnio E. Patient-Associated Characteristics Influencing the Risk for Non-Persistence with Statins in Older Patients with Peripheral Arterial Disease. Drugs Aging 2019; 36 (9): 863-873. (IF(2019)=2,824) jcr – Q2

2

Wawruch M, Zatko D, Wimmer G Jr, Luha J, Kuzelova L, Kukumberg P, Murin J, Hloska A, Tesar T, Kallay Z, Shah R. Factors Influencing Non-Persistence with Antiplatelet Medications in Elderly Patients After Ischaemic Stroke. Drugs Aging 2016; 33 (5): 365-73. (IF(2016)=2,769) jcr – Q2 

3

Wawruch M, Macugova A, Kostkova L, Luha J, Dukat A, Murin J, Drobna V, Wilton L, Kuzelova M. The use of medications with anticholinergic properties and risk factors for their use in hospitalised elderly patients. Pharmacoepidemiol Drug Saf. 2012; 21 (2): 170-6. (IF(2012)=2,897) jcr – Q2 

4

Wawruch M, Dukat A, Murin J, Wsolova L, Kuzelova M, Macugova A, Wimmer G Jr, Shah R. The effect of selected patient's characteristics on the choice of antihypertensive medication in the elderly in Slovakia. Pharmacoepidemiol Drug Saf 2009; 18 (12): 1199-1205. (IF(2009)=2,527) jcr – Q2  

5

Wawruch M, Wimmer G Jr, Murin J, Paduchova M, Petrova M, Tesar T, Matalova P, Havelkova B, Trnka M, Aarnio E. Non-Adherence to Statin Treatment in Older Patients with Peripheral Arterial Disease Depending on Persistence Status. Biomedicines. 2020; 8 (10): 378. (IF(2020)=6,081) jcr – Q1

VI.3 - The most significant research/artistic/other outputs over the last six years
1

Wawruch M, Petrova M, Tesar T, Murin J, Schnorrerova P, Paduchova M, Celovska D, Havelkova B, Trnka M, Alfian SD, Aarnio E. Factors associated with non-adherence to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in older patients with peripheral arterial disease. Front Pharmacol. 2023; 14: 1199669. (IF(2022)=5,6) jcr – Q1

2

Wawruch M, Murin J, Tesar T, Petrova M, Paduchova M, Celovska D, Havelkova B, Trnka M, Masarykova L, Alfian SD, Aarnio E. Reinitiation and Subsequent Discontinuation of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers among New and Prevalent Users Aged 65 Years or More with Peripheral Arterial Disease. Biomedicines. 2023 ; 11 (2): 368. doi: 10.3390/biomedicines11020368. (IF(2022)=4,7) jcr – Q2

3

Wawruch M, Murin J, Tesar T, Paduchova M, Petrova M, Celovska D, Havelkova B, Trnka M, Aarnio E. Non-Persistence With Antiplatelet Medications Among Older Patients With Peripheral Arterial Disease. Front Pharmacol. 2021; 12: 687549. (IF(2021)=5,988) jcr – Q1

4

Wawruch M, Wimmer G Jr, Murin J, Paduchova M, Tesar T, Hlinkova L, Slavkovsky P, Aarnio E. Factors Associated with Reinitiation of Statin Treatment in Older Patients with Peripheral Arterial Disease. Drugs Aging 2020; 37 (8): 595-604. (IF(2020)=3,923) jcr – Q2

5

Wawruch M, Petrova M, Celovska D, Alfian SD, Tesar T, Murin J, Trnka M, Paduch T, Aarnio E. Non-persistence with multiple secondary prevention medications for peripheral arterial disease among older hypertensive patients. Front Pharmacol. 2024; 15: 1464689. (2023: 4,4 – IF, Q1 – JCR)

VI.4 - The most significant citations corresponding to the research/artistic/other outputs
1

Wawruch M, Wimmer G Jr, Murin J et al. Patient-Associated Characteristics Influencing the Risk for Non-Persistence with Statins in Older Patients with Peripheral Arterial Disease. Drugs Aging 2019; 36 (9): 863-873. CITATION: Youens, D. - Doust, J. - Robinson, S. - Moorin, R.: Journal of General Internal Medicine, vol. 36, no. 6, 2021, s. 1656-1665 

2

Wawruch M, Macugova A, Kostkova L et al. The use of medications with anticholinergic properties and risk factors for their use in hospitalised elderly patients. Pharmacoepidemiol Drug Saf. 2012; 21 (2): 170-6. CITATION: Nishtala, P.S. - Salahudeen, M.S. - Hilmer, S.N.: Expert Opinion on Drug Safety, vol. 15, no. 6, 2016, s. 753-768.

3

Wawruch M, Zatko D, Wimmer G Jr et al. Patient-related characteristics associated with non-persistence with statin therapy in elderly patients following an ischemic stroke. Pharmacoepidemiol Drug Saf 2017; 26 (2): 201-207. CITATION: Ofori-Asenso, R. - Ilomäki, J. - Tacey, M. et al.: British Journal of Clinical Pharmacology, vol. 85, no. 1, 2019, s. 227-235.

4

Wawruch M, Zatko D, Wimmer G J et al. Factors Influencing Non-Persistence with Antiplatelet Medications in Elderly Patients After Ischaemic Stroke. Drugs Aging 2016; 33 (5): 365-73. CITATION: Dalli, L.L. - Kim, J. - Thrift, A.G. et al.: Neurology, vol. 96, no.1, 2021, s. E30-E41 - SCI

5

Wawruch M, Zatko D, Wimmer G Jr et al. Age-Related Differences in Non-Persistence with Statin Treatment in Patients after a Transient Ischaemic Attack. Clin Drug Investig 2017; 37 (11): 1047-1054. CITATION: van Dongen, M.M.E. - Aarnio, K. -Martinez-Majander, N. et al.: Stroke, vol. 50, no. 12, 2019, s. 3385-3392

VI.5 - Participation in conducting (leading) the most important research projects or art projects over the last six years
1

VEGA 1/0135/09 “Specific features of pharmacotherapy in geriatrics and the possibilities of its quality assessment” (principal investigator)

2

VEGA 1/0886/14 “Suboptimal use of drugs in secondary prevention of cardiovascular diseases in older patients” (principal investigator)

3

VEGA 1/0112/17 “Adherence to pharmacotherapy – a basic precondition of successful secondary prevention of cardiovascular diseases in older patients” (principal investigator)

4

VEGA 1/0024/21 “Possibilities of pharmacoepidemiologic analysis of adherence to preventive pharmacotherapy in older patients with peripheral arterial disease of lower limbs” (principal investigator)

5

2020-2024 The European Cooperation in Science and Technology COST CA19132 “European Network to Advance Best practices & technoLogy on medication adherencE (ENABLE)” (co-investigator)

VII. - Overview of organizational experience related to higher education and research/artistic/other activities

VII.a - Activity, position VII.b - Name of the institution, board VII.c - Duration
Member of the Board of Student Scientific Activity Comenius University in Bratislava, Faculty of Medicine 2007 - 2015
Memeber of Editorial Board joutnal: Klinická farmakologie a farmacie, SOLEN 2008 - until now
Board Member of the Slovak Pharmcological Society Slovak Medical Society 2012 - until now
Board Member of the Slovak Society of Clinical Pharmacology Slovak Medical Society 2007 - until now
Executive Committee member European Drug Utilization Research Group 2023 - until now

VIII. - Overview of international mobilities and visits oriented on education and research/artistic/other activities in the given field of study

VIII.a - Name of the institution VIII.b - Address of the institution VIII.c - Duration (indicate the duration of stay) VIII.d - Mobility scheme, employment contract, other (describe)
University of Eastern Finland Yliopistokatu 2, Aurora building, Kuopio, Fínsko / Finland 2018 until now scientific cooperation with Dr. Emma Aarnio, PhD.
Medicines and Healthcare Products Regulatory Agency 10 S Colonnade, London E14 4PU, London, UK 2008 -2017 scientific cooperation with Dr. Rashmi Shah
Drug Safety Research Unit Bursledon Hall, Blundell Ln, Bursledon, Southampton SO31 1AA, UK 2008 - 2012 scientific cooperation with Dr. Lynda Wilton
University of Szeged Dugonics tér 13, 6720, Szeged, Maďarsko / Hungary 2011 - until now cooperation with Dr. Ria Benko within European Drug Utilisation Research Group
University of Debrecen Egyetem tér 1, 4032, Debrecen, Hungary 2003 - 2014 cooperation with Prof. Adam Vas in Clinical Pharmacology
Univerzita Palackého Křížkovského 511/8, 771 47 Olomouc, Czech Republic 2007 - until now scientific cooperation with Dr. Petra Matálová and Assoc. Prof. Karel Urbánek

IX. - Other relevant facts

IX.a - If relevant, other activities related to higher education or research/artistic/other activities are mentioned

Reviewer of journals: Bratislava Medical Journal, Acta Medica Martiniana, International Journal of Endocrinology, Human and Experimental Toxicology, Drugs and Aging, Frontiers in Pharmacology, Biomedicines, Biomolecules, CNS Drugs, American Journal of Cardiovascular Drugs

Date of last update
2025-01-24